Ascidian Therapeutics

News

In its third big licensing deal of the week, Eli Lilly has tapped RNA-editing specialist Ascidian for kidney disease therapies in a $1.9bn alliance.

News

TransThera's Yochanra has been cleared in China as the world's first drug that can overcome resistance to FGFR inhibitors in cholangiocarcinoma.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.